Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of Incyte stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the transaction, the executive vice president owned 37,701 shares in the company, valued at approximately $2,569,323.15. The trade was a 18.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Incyte Stock Up 1.6%
Shares of INCY traded up $1.05 during trading hours on Wednesday, hitting $68.72. 1,927,153 shares of the company were exchanged, compared to its average volume of 1,961,300. The company has a market cap of $13.30 billion, a PE ratio of 214.76, a PEG ratio of 0.57 and a beta of 0.68. The firm's 50 day moving average is $65.94 and its 200-day moving average is $66.67. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $83.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.00 and a current ratio of 2.04.
Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. Incyte had a net margin of 0.48% and a return on equity of 2.77%. The business's revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 EPS. On average, equities research analysts forecast that Incyte Corporation will post 4.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Sivia Capital Partners LLC lifted its position in Incyte by 147.9% during the 2nd quarter. Sivia Capital Partners LLC now owns 12,077 shares of the biopharmaceutical company's stock worth $822,000 after acquiring an additional 7,206 shares during the last quarter. Krilogy Financial LLC increased its holdings in shares of Incyte by 61.2% during the 2nd quarter. Krilogy Financial LLC now owns 17,883 shares of the biopharmaceutical company's stock worth $1,218,000 after purchasing an additional 6,792 shares during the period. Czech National Bank increased its holdings in shares of Incyte by 6.4% during the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company's stock worth $2,674,000 after purchasing an additional 2,378 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Incyte by 26.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,448 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 299 shares during the period. Finally, Parallel Advisors LLC increased its holdings in shares of Incyte by 8.9% during the 2nd quarter. Parallel Advisors LLC now owns 4,832 shares of the biopharmaceutical company's stock worth $329,000 after purchasing an additional 393 shares during the period. Institutional investors and hedge funds own 96.97% of the company's stock.
Analysts Set New Price Targets
INCY has been the topic of several research analyst reports. Wells Fargo & Company lifted their price objective on shares of Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. JPMorgan Chase & Co. decreased their target price on shares of Incyte from $70.00 to $68.00 and set a "neutral" rating for the company in a research note on Monday, April 21st. Royal Bank Of Canada set a $67.00 target price on shares of Incyte and gave the company a "sector perform" rating in a research note on Monday, June 23rd. Morgan Stanley decreased their target price on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. Finally, Wall Street Zen raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $74.53.
Read Our Latest Analysis on INCY
Incyte Company Profile
(
Get Free Report)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Recommended Stories

Before you consider Incyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.
While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.